Perakizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | IL17A |
| Clinical data | |
| ATC code | none |
| Identifiers | |
| CAS Number | 89957-37-9 |
| ChemSpider | none |
| Chemical and physical data | |
| Formula | C6454H9964N1718O2030S44 |
| Molar mass | 145.4 kg/mol |
Perakizumab (INN) is a humanized monoclonal antibody designed for the treatment of arthritis.[1] It binds to IL17A and acts as an immunomodulator.[2]
This drug was developed by Genentech/Roche.
References
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Perakizumab, American Medical Association.
- ↑ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).
This article is issued from Wikipedia - version of the 6/4/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.